Stability of Venlafaxine Immediate-Release Suspensions

Donnelly, Ronald F; Wong, Keith; Goddard, Rob; Johanson, Christel

Abstract

Stability of Venlafaxine Immediate-Release Suspensions

Author(s): Donnelly Ronald F, Wong Keith, Goddard Rob, Johanson Christel

Issue: Jan/Feb 2011 - Volume 15, Number 1

View All Articles in Issue

Page(s): 81-84

Download in electronic PDF format for $75

Note: Electronic version includes errata or revisions.

Abstract

Venlafaxine is a novel antidepressant that works by inhibiting the reuptake of serotonin and norepinephrine. The objectives of this study were to reformulate a venlafaxine extended-release suspension into an immediate-release preparation and then determine the physical and chemical stability of the new venlafaxine formulation. Suspensions of venlafaxine (75 mg/5mL) were prepared from extended-release microspheres that had been reduced to powder and then dispersed in either OraPlus/OraSweet (50:50) or simple syrup. Triplicate samples of the suspensions were collected from amber plastic bottles stored at either 5ºC or 23ºC on days 0, 7, 14, 21, and 28, and assayed. Physical stability was based on color and pH changes. A validated high-performance liquid chromatography assay method was used to determine the chemical stability of the active ingredient. This study found that venlafaxine immediate-release suspensions, prepared in either OraPlus/OraSweet or simple syrup, are physically and chemically stable for 28 days when stored in amber plastic bottles at either 5ºC or 23ºC.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jan/Feb 2011 Pg. 81-84	Stability of Venlafaxine Immediate-Release Suspensions Author(s): Donnelly Ronald F, Wong Keith, Goddard Rob, Johanson Christel
Mar/Apr 2011 Pg. 175	Erratum: Stability of Venlafaxine Immediate-Release Suspensions Author(s): Allen Loyd V Jr
May/Jun 2009 Pg. 259-261	Formulation Optimization Study for an Immediate-Release Tablet Author(s): Kyriacos Soula, Dimassi Hani
Sep/Oct 2021 Pg. 364-371	Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products Author(s): Uttaro Elizabeth, Zhao Fang, Schweighardt Anne
Sep/Oct 2017 Pg. 418-425	Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3) Author(s): Bakhteyar Hamid, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
May/Jun 2020 Pg. 233	Venlafaxine 15 mg/mL in Ora-Plus:Ora-Sweet (1:1) Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
Jan/Feb 2013 Pg. 10-22	Compounding Slow-release Capsules: A Comprehensive Review and an Excel Spreadsheet for Faster Calculation of Excipients Author(s): Zur Eyal
Sep/Oct 2001 Pg. 401-405	Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release Author(s): Bogner Robin H, Szwejkowski Jessica, Houston Alana
Mar/Apr 1997 Pg. 128-131	Stability of Allopurinol Suspension Compounded from Tablets Author(s): Alexander Kenneth S, Davar Nipun, Parker Gordon A
Jan/Feb 2020 Pg. 63	Venlafaxine 15 mg/mL in Syrup Author(s): Allen Loyd V Jr
Sep/Oct 2023 Pg. 431-439	The Influence of Polymers, Surfactants, and Other Excipients on Naproxen Sodium Release from Matrices Prepared and the Effect of These Additives on the Swelling Rate of the Tablet Author(s): Alhmoud Hassan, Akkam Yazan, Omari Derar, Alghananim Alaa, Melhem Mohammad Bani
Sep/Oct 2013 Pg. 424-431	In Vitro Evaluation of Extemporaneously Compounded Immediate-release Capsules with Premixed Excipients, Based on the Biopharmaceutics Classification System (BCS) of the Drugs Author(s): Pinheiro Vanessa A, Danopoulos Panagiota, Demirdjian Lara, Nogueira Rodrigo J L, Dubois Fanny
Jan/Feb 2022 Pg. 65-71	Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management Author(s): Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
Sep/Oct 2021 Pg. 431-439	Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Jul/Aug 2017 Pg. 322-329	Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
Jul/Aug 2022 Pg. 283-291	Evaluation of the Physical-chemical Characteristics and Biopharmaceutical Performance of Dilu-Cap: A Complete Line of Excipients for Hard-shell Capsules Author(s): de Oliveira Ferreira Anderson, Polonini Hudson
Mar/Apr 2017 Pg. 160-163	Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions Author(s): Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
May/Jun 2003 Pg. 233-239	Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Author(s): Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
Jan/Feb 2023 Pg. 72-77	Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base Author(s): Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio